Kennedy pathway enzymes

The Kennedy pathway enzymes constitute the essential metabolic route for the de novo synthesis of phosphatidylcholine and phosphatidylethanolamine, the primary structural phospholipids of eukaryotic cell membranes (Gibellini & Smith, 2010). This pathway is divided into two branches—the CDP-choline and CDP-ethanolamine pathways—each involving three conserved enzymatic steps: phosphorylation by kinases, activation by cytidylyltransferases, and final linkage to a lipid anchor by phosphotransferases (Vance, 2015). These enzymes are vital for maintaining membrane integrity, supporting cell growth, and regulating lipid-mediated signaling (Glunde et al., 2011). In oncology, enzymes such as Choline kinase alpha (CKα) are frequently overexpressed to meet the increased demand for membrane biogenesis in proliferating tumor cells, making them significant targets for drug development (Awwad et al., 2019). Pharmacological inhibitors like TCD-717 target these enzymes to disrupt phospholipid homeostasis, leading to cell cycle arrest and apoptosis in various cancers (Lacal & Campos, 2015). Beyond cancer, the Kennedy pathway is a focus in research regarding neurodegenerative diseases and parasitic infections, where the pathway's enzymes are critical for the survival of pathogens like Plasmodium falciparum (Vance & Vance, 2004).

Other names

CDP-choline pathwayCDP-ethanolamine pathwayDe novo phospholipid biosynthetic pathwayCholine metabolism pathway

Inhibition of de novo phospholipid biosynthesis, primarily through the inhibition of Choline kinase alpha or CTP:phosphocholine cytidylyltransferase, leading to impaired membrane production and induction of apoptosis.